Experienced in Hereditary Neuralgic Amyotrophy

Ari Breiner

Ottawa, ON, CA 
Experienced in Hereditary Neuralgic Amyotrophy
Ottawa, ON, CA 
OverviewLocationsClinical Research

Overview

Ari Breiner practices in Ottawa, Canada. Mr. Breiner is rated as an Experienced expert by MediFind in the treatment of Hereditary Neuralgic Amyotrophy. His top areas of expertise are Sensorimotor Polyneuropathy, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Thymectomy.

His clinical research consists of co-authoring 92 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hereditary Neuralgic Amyotrophy.

Gender
Male

Locations

Ottawa, ON, Canada
Other Locations
Toronto, Canada
200 Elizabeth Street, Room 5EB-306A, M5G 2C4, Toronto, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients
Enrollment Status: Completed
Publish Date: December 20, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 24-Week, Phase 2a Study of Topical Pirenzepine (WST-057) or Placebo in Type 2 Diabetic Patients With Peripheral Neuropathy
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 24-Week, Phase 2a Study of Topical Pirenzepine (WST-057) or Placebo in Type 2 Diabetic Patients With Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: December 16, 2022
Intervention Type: Drug
Study Drug: WST-057 Pirenzepine Free Base Monohydrate
Study Phase: Phase 2
View 1 Less Clinical Trial

92 Total Publications

Atypical features including acquired oculomotor apraxia in C9orf72-associated familial primary lateral sclerosis.
Atypical features including acquired oculomotor apraxia in C9orf72-associated familial primary lateral sclerosis.
Journal: Journal of neuromuscular diseases
Published: September 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Breiner's expertise for a condition
ConditionClose
    View All 32 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile